...
首页> 外文期刊>Allergy, Asthma & Clinical Immunology >Severity and disease control before house dust mite immunotherapy initiation: ANTARES a French observational survey
【24h】

Severity and disease control before house dust mite immunotherapy initiation: ANTARES a French observational survey

机译:屋尘螨免疫治疗开始之前的严重程度和疾病控制:ANTARES法国观察性调查

获取原文
           

摘要

Background Allergen immunotherapy (AIT) may be prescribed for patients with allergic rhinitis (AR) induced by house dust mites (HDM) whether asthma is present or not. Current guidelines provide insufficient support for therapeutic management strategy of these patients. Allergists however have long-term experience with AIT. This study aims to describe the characteristics of the patients seen in clinical practice with HDM allergy and the process used to determine whether AIT should be initiated. Methods This was an observational, multicenter, prospective and cross-sectional study, conducted in France from 2013 to 2014 with a representative sample of allergy specialists. Any patient over 5?years of age with confirmed HDM allergy untreated with AIT within the last 12?months was eligible. Data were prospectively collected using physician and patient questionnaires. Results A total of 1589 patients (60?% adults, 40?% children) were included by 195 randomly selected allergists. A subgroup of 1212 patients (median age: 22?years; 52?% women) were selected for AIT treatment with a median time of AR diagnosis of 3?years. Amongst these, 59?% had a moderate to severe persistent AR according to AR and its Impact on Asthma guidelines, 57.5?% were polysensitized, and 56.5?% also suffered from conjunctivitis (median rhinitis total symptom score: 11). Asthma was present in 42?% of patients, and was controlled according to Global Initiative for Asthma guidelines in 62?% of patients. The asthma control questionnaire score was 1–1.5 in 20?% and?≥1.5 in 37?% of patients. A total of 57?% patients received a prescription of?≥2 medications (mainly antihistamines). Usual daily activities and sleep quality were slightly-to-moderately impaired as the mean rhinoconjunctivitis quality of life questionnaire score was 2.7?±?1.5. The major driver of AIT prescription is AR uncontrolled by previous medications leading to patient dissatisfaction. Conclusions HDM-AR associated conjunctivitis was present in 60?% and asthma in 40?% of cases. In?>40?% of these cases, asthma was inadequately controlled at the start of AIT.
机译:背景技术无论是否存在哮喘,对于因屋尘螨(HDM)诱发的过敏性鼻炎(AR)的患者,都可以开具变应原免疫疗法(AIT)。当前的指南没有为这些患者的治疗管理策略提供足够的支持。但是,过敏症患者具有AIT的长期经验。这项研究旨在描述在临床实践中对HDM过敏患者的特征,以及用于确定是否应启动AIT的过程。方法这是一项观察性,多中心,前瞻性和横断面研究,于2013年至2014年在法国进行,其中有代表性的过敏专家样本。在过去的12个月内未接受AIT治疗的任何5岁以上已确诊HDM过敏的患者均符合资格。使用医师和患者调查表前瞻性收集数据。结果随机选择的195名过敏症患者共纳入1589名患者(成人60%,儿童40%)。选择1212名患者(中位年龄:22岁;女性52%)作为亚组进行AIT治疗,AR诊断的中位时间为3年。其中,根据AR及其对哮喘的影响,有59%的人患有中度至重度持续性AR,有57.5%的人患有多敏性,还有56.5%的人患有结膜炎(中位鼻炎总症状评分:11)。哮喘存在于42%的患者中,并根据62%的患者根据全球哮喘防治指南进行了控制。哮喘控制问卷评分在20%的患者中为1-1.5,在37%的患者中为≥1.5。共有57%的患者接受了≥2种药物(主要是抗组胺药)的处方。由于鼻结膜炎生活质量问卷的平均得分为2.7±1.5,因此日常日常活动和睡眠质量略有中度降低。 AIT处方的主要驱动因素是AR不受以前药物的控制,导致患者不满意。结论HDM-AR相关性结膜炎占60%,哮喘占40%。在这些病例中,> 40 %%的患者在AIT开始时哮喘控制不充分。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号